Chondrocytic and pharmacokinetic properties of Phlpp inhibitors

Keyphrases

• Glycosaminoglycans 100%
• Articular Cartilage 100%
• Pharmacokinetic Properties 100%
• Histology 50%
• Western Blotting 50%
• Pharmacokinetics 50%
• Intravenous Injection 50%
• Pharmacodynamics 50%
• Intra-articular Injection 50%
• Phosphatase 50%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 50%
• Highly Stable 50%
• Putative Drug Targets 50%
• Protein Phosphatase 50%
• Chondrocytes 50%
• Inhibitory Effect 50%
• Bloodstream 50%
• Two-level 50%
• Activity in Vivo 50%
• Matrix Production 50%
• Medial Tibial Plateau 50%
• Cartilage Formation 50%
• Matrix Degradation 50%
• Leucine-rich Repeat Protein 50%
• Volume Distribution 50%
• Femoral Condyle 50%
• Pleckstrin Homology Domain 50%
• Lateral Tibial Plateau 50%
• Cartilage Regeneration 50%
• Collagen Type 2 50%
• Chondrocyte Proliferation 50%
• Proteoglycan 4 (PRG4) 50%
• Transcriptomic Assay 50%
• SRY-box Transcription Factor 9 (SOX9) 50%
• Cartilage Structure 50%
• Osteoarthritic Joint 50%

Biochemistry, Genetics and Molecular Biology

• Pharmacokinetic Properties 100%
• Chondrocyte 100%
• Glycosaminoglycan 100%
• Western Blot 50%
• Leucine-Rich Repeat 50%
• Pharmacodynamics 50%
• Pleckstrin Homology Domain 50%
• Transcriptomics 50%
• Chromatography 50%
• Phosphoprotein Phosphatase 50%
• Pharmacokinetics 50%
• Proteoglycan 50%
• Phosphatase 50%
• Repeat Protein 50%

Veterinary Science and Veterinary Medicine

• In Vitro 100%
• Chondrocyte 66%
• Glycosaminoglycan 66%
• Articular Cartilage 66%
• Cartilage 66%
• Mouse 33%
• Femoral Condyle 33%
• Joint Injection 33%
• Intraarticular Drug Administration 33%
• Medial Tibial Plateau 33%
• Histology 33%
• Transcriptomics 33%